TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05433142: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Sponsor: Xencor, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 307 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$848,232

Rescue Site Savings

+$565,488

Unlock Full NCT05433142 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05433142 Rescue Dossier →